Furthermore, targeting ACAT1, the enzyme that catalyzes the esterification of cholesterol, through inhibition or ablation, has demonstrated the potential to decrease Aβ and tau pathology in mouse models of AD. This evidence concerns the gene MAPT and Alzheimer disease.